Abstract
The breaking of immune tolerance against autologous angiogenic endothelial cells should be a useful approach for cancer therapy. Here we show that immunotherapy of tumors using fixed xenogeneic whole endothelial cells as a vaccine was effective in affording protection from tumor growth, inducing regression of established tumors and prolonging survival of tumor-bearing mice. Furthermore, autoreactive immunity targeting to microvessels in solid tumors was induced and was probably responsible for the anti-tumor activity. These observations may provide a new vaccine strategy for cancer therapy through the induction of an autoimmune response against the tumor endothelium in a cross-reaction.
Publication types
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Amino Acid Sequence
-
Animals
-
Antigens, CD / immunology
-
Autoantibodies / immunology
-
CD4-Positive T-Lymphocytes / immunology
-
Cancer Vaccines / pharmacology*
-
Cattle
-
Cells, Cultured
-
Cross Reactions
-
Endothelium / cytology*
-
Endothelium / immunology*
-
Endothelium, Vascular / cytology
-
Endothelium, Vascular / immunology
-
Humans
-
Immunotherapy / methods*
-
Integrin alphaV
-
Mice
-
Molecular Sequence Data
-
Neoplasms, Experimental / therapy*
-
Neovascularization, Pathologic / drug therapy
-
Neovascularization, Pathologic / immunology
-
Peptides / immunology
-
Receptor Protein-Tyrosine Kinases / immunology
-
Receptors, Growth Factor / immunology
-
Receptors, Vascular Endothelial Growth Factor
Substances
-
Antigens, CD
-
Autoantibodies
-
Cancer Vaccines
-
Integrin alphaV
-
Peptides
-
Receptors, Growth Factor
-
Receptor Protein-Tyrosine Kinases
-
Receptors, Vascular Endothelial Growth Factor